MA52238A - Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées - Google Patents

Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées

Info

Publication number
MA52238A
MA52238A MA052238A MA52238A MA52238A MA 52238 A MA52238 A MA 52238A MA 052238 A MA052238 A MA 052238A MA 52238 A MA52238 A MA 52238A MA 52238 A MA52238 A MA 52238A
Authority
MA
Morocco
Prior art keywords
drug conjugates
bonding agents
associated uses
cmet monoclonal
cmet
Prior art date
Application number
MA052238A
Other languages
English (en)
Inventor
Vincent Blot
Julia Coronella
Ryo Fujita
Marco Gymnopoulos
Roland Newman
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MA52238A publication Critical patent/MA52238A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
MA052238A 2018-03-28 2019-03-27 Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées MA52238A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862649078P 2018-03-28 2018-03-28

Publications (1)

Publication Number Publication Date
MA52238A true MA52238A (fr) 2021-02-17

Family

ID=68059106

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052238A MA52238A (fr) 2018-03-28 2019-03-27 Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées

Country Status (14)

Country Link
US (1) US20210163604A1 (fr)
EP (1) EP3774923A4 (fr)
JP (2) JP7177848B2 (fr)
KR (1) KR20200138288A (fr)
CN (1) CN112119098A (fr)
AU (1) AU2019243764A1 (fr)
BR (1) BR112020019465A2 (fr)
CA (1) CA3094827A1 (fr)
IL (1) IL277573A (fr)
MA (1) MA52238A (fr)
MX (1) MX2020010110A (fr)
PH (1) PH12020551556A1 (fr)
SG (1) SG11202009308WA (fr)
WO (1) WO2019189453A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111363042B (zh) * 2020-03-30 2022-02-11 中国人民解放军第四军医大学 一种高特异性抗小鼠cd226单克隆抗体及其应用
AU2022218165B2 (en) * 2021-02-03 2024-02-29 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
EP4320152A1 (fr) * 2021-04-08 2024-02-14 Byondis B.V. Anticorps anti-c-met et conjugués anticorps-médicament

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1981981T1 (sl) 2006-02-06 2012-01-31 Metheresis Translational Res Sa Anti-met monoklonalno protitelesce, njegovi fragmenti in vektorji, za zdravljenje tumorjev in ustrezni proizvodi
US7910702B2 (en) * 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
EP2257293A2 (fr) * 2008-03-06 2010-12-08 Genentech, Inc. Thérapie combinée par des antagonistes de c-met et egfr
CA2833019A1 (fr) * 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Proteines de liaison a un antigene membranaire specifique de la prostate et compositions et procedes associes
WO2014062659A2 (fr) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de maladies oculaires
GB201317982D0 (en) * 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015161311A2 (fr) * 2014-04-18 2015-10-22 The Research Foundation For The State University Of New York Anticorps humanisés anti-antigène tf
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
SG11201704458SA (en) * 2014-12-08 2017-06-29 Sorrento Therapeutics Inc C-met antibody drug conjugate
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201204A1 (fr) * 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. Conjugués anticorps-médicament anti-cmet et méthodes d'utilisation de ces conjugués
HUE054571T2 (hu) * 2016-09-14 2021-09-28 Merck Patent Gmbh Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
US11299547B2 (en) * 2016-09-29 2022-04-12 Mitsubishi Tanabe Pharma Corporation CMET monoclonal binding agents, drug conjugates thereof and uses thereof

Also Published As

Publication number Publication date
JP2023025034A (ja) 2023-02-21
WO2019189453A1 (fr) 2019-10-03
KR20200138288A (ko) 2020-12-09
JP7177848B2 (ja) 2022-11-24
RU2020135303A (ru) 2022-04-28
CN112119098A (zh) 2020-12-22
MX2020010110A (es) 2020-11-06
AU2019243764A1 (en) 2020-11-05
PH12020551556A1 (en) 2021-06-07
IL277573A (en) 2020-11-30
BR112020019465A2 (pt) 2021-01-12
SG11202009308WA (en) 2020-10-29
JP2021519319A (ja) 2021-08-10
EP3774923A4 (fr) 2021-12-29
CA3094827A1 (fr) 2019-10-03
TW201946656A (zh) 2019-12-16
US20210163604A1 (en) 2021-06-03
EP3774923A1 (fr) 2021-02-17

Similar Documents

Publication Publication Date Title
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
MA49270A (fr) Récepteurs de liaison à l'antigène améliorés
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA43576A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
EA201890130A1 (ru) Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
MA55868A (fr) Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation
MA47468A (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
MA52238A (fr) Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3873931A4 (fr) Anticorps anti-cd79b, conjugués anticorps-médicaments et utilisations associées
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
MA51147A (fr) Associations d'anticorps anti-c5 et utilisations associées
EP3612567A4 (fr) Anticorps anti-vtcn1 et conjugués anticorps-médicament
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
MA54052A (fr) Formulation d'anticorps
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
MD3691692T2 (ro) Conjugaţi medicament anticorp activabili anti-CD71 și metode de utilizare a acestora
WO2018111670A3 (fr) Anticorps dirigés contre l'alpha-synucléine humaine